ATLANTA, May 16, 2006 (PRIMEZONE) -- Market-Pulse.com announces its trade alert for DNAPrint Genomics, Inc. (OTCBB:DNAG). According to Bernard R. Schmitt of Market Pulse, "The company just had excellent news out today regarding its Computational Biology Division completed a pre-clinical, first generation computational model of the characteristics and mechanisms of its PT-401 drug under development for the treatment of anemia." PT-401 is a potential competitor in the EPO market that exceeds $11 billion and is rapidly growing.
DNAPrint Pharmaceuticals is working on the development of "theranostic" genetic test/drug combinations designed to improve a drug's efficacy and reduce potential side effects. PT-401 is the lead drug in DNAPrint's product pipeline. PT-401 is a "Super EPO," a more powerful form of erythropoietin, a well-known drug used for the treatment of anemia.
In a press release issued earlier today by DNAPrint, "We are beginning to reap the benefits of computational biology technology acquired by the Company in November 2005," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "This first generation of EPOFusion(tm) is designed to support the basic science studies required for drugs before human testing. Our Computational Biology Division will be advancing EPOFusion(tm) to a second generation model, using knowledge gained in the preclinical phase, for an expanded version (EPOFusion(tm) II) used to simulate clinical (human) studies."
The EPOFusion(tm) model simulates the cellular and molecular dynamics influenced by the administration of the erythropoietin class of protein drugs in anemia treatments. EPOFusion(tm) models the interaction of PT-401 -- a novel 2-copy (dimer) form of erythropoietin -- with the cells that trigger the production of new red blood cells. EPOFusion(tm)can be manipulated to test hundreds of conditions and variables by simulating what occurs in the whole blood cell production process. The EPOFusion(tm) model has already identified important differences between PT-401 and currently marketed drugs or drugs in development by other companies. This type of information may provide a competitive advantage and is critical for transparent regulatory filings and effective physician education upon FDA approval of a drug for clinical testing.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end-stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(tm), RETINOME(tm), ANCESTRYbyDNA(tm) and EURO-DNA(tm). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
About Market-Pulse.com
Market Pulse LLC, the owner and operator of Market-Pulse.com (collectively referred to as "MP"), is a leading investor relations firm whose primary focus is promoting awareness among brokers, investors, and others in the investment community who are interested in small- and micro-cap companies. MP is dedicated to helping publicly traded companies gain the exposure they need to move forward with the development of their business plans. MP's goal is to feature equity investments in micro or small capitalization companies that have the potential for long-term appreciation. MP provides investors with a complete suite of online interactive financial data and tools that includes quotes, charts, company profiles, news, market commentary and SEC filings, just to name a few. MP offers a free financial newsletter. To subscribe or get more information, visit our home page located at www.market-pulse.com.
Information contained herein is the opinion of MP and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.
MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.
You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated two hundred twenty-five thousand dollars from DNAPrint Genomics, Inc. MP was also compensated six million restricted shares of common stock directly from DNAPrint Genomics, Inc. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services.